Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy
Kuan-Chang Lai, Yen-Hao Chen, Yi‑Ping Hung, Nai-Jung Chiang, Ming‑Huang Chen, San-Chi Chen · 2024
Read Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy by Kuan-Chang Lai, Yen-Hao Chen, Yi‑Ping Hung, Nai-Jung Chiang, Ming‑Huang Chen, San-Chi Chen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11632046.txt.
Description
Kuan-Chang Lai and co-authors test a second immune drug after the first fails in liver cancer in a 2024 study. Checkpoint drugs are approved for this cancer now. Whether switching class after failure helps was unknown. A drug against the partner checkpoint was the retry.
Sixty-five advanced patients received the second drug after prior failure. Most had previously received one specific first drug. About fourteen percent responded to the retry overall. Prior responders answered the retry at triple the rate. Immune side effects during retry also marked better odds. Median survival ran under ten months overall. Prior responders lived far longer after retry than non-responders. That prior response was the sole protective factor found. Skin and liver inflammation were the common side effects. The authors support selective rechallenge after checkpoint failure. Prior benefit is the screening signal for offering it.
Catalog record
| CREATOR | Kuan-Chang Lai, Yen-Hao Chen, Yi‑Ping Hung, Nai-Jung Chiang, Ming‑Huang Chen, San-Chi Chen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |